상세 보기
Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study
- Assmann, C.;
- Yang, J. Chih-Hsin;
- Kim, Y. Jung;
- Lee, S. -H.;
- Liu, B.;
- 외 16명
Citations
WEB OF SCIENCE
0Citations
SCOPUS
0- 제목
- Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study
- 저자
- Assmann, C.; Yang, J. Chih-Hsin; Kim, Y. Jung; Lee, S. -H.; Liu, B.; Ostapenko, Y.; Lu, S.; Alip, A.; Korbenfeld, E.; Dias, J. Mourao; Danchaivijitr, P.; Girard, N.; Felip, E.; Hayashi, H.; Spira, A. I.; Besse, B.; Sun, T.; Ennis, M.; Sethi, S.; Bauml, J. M.; Cho, B. C.
- 발행일
- 2025-10-20
- 유형
- Meeting Abstract
- 권
- 48
- 호
- SUPPL 2